Crinetics Pharmaceuticals Statistics
Total Valuation
CRNX has a market cap or net worth of $4.13 billion. The enterprise value is $3.15 billion.
Important Dates
The next confirmed earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CRNX has 104.71 million shares outstanding. The number of shares has increased by 16.43% in one year.
| Current Share Class | 104.71M |
| Shares Outstanding | 104.71M |
| Shares Change (YoY) | +16.43% |
| Shares Change (QoQ) | +0.94% |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 102.01% |
| Float | 96.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 536.59 |
| Forward PS | 65.82 |
| PB Ratio | 3.80 |
| P/TBV Ratio | 4.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 409.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.32, with a Debt / Equity ratio of 0.05.
| Current Ratio | 12.32 |
| Quick Ratio | 12.09 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.17% and return on invested capital (ROIC) is -26.72%.
| Return on Equity (ROE) | -40.17% |
| Return on Assets (ROA) | -25.22% |
| Return on Invested Capital (ROIC) | -26.72% |
| Return on Capital Employed (ROCE) | -49.63% |
| Weighted Average Cost of Capital (WACC) | 5.86% |
| Revenue Per Employee | $12,956 |
| Profits Per Employee | -$783,362 |
| Employee Count | 594 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CRNX has paid $180,000 in taxes.
| Income Tax | 180,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.59% in the last 52 weeks. The beta is 0.31, so CRNX's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +42.59% |
| 50-Day Moving Average | 40.79 |
| 200-Day Moving Average | 40.04 |
| Relative Strength Index (RSI) | 55.17 |
| Average Volume (20 Days) | 1,235,612 |
Short Selling Information
The latest short interest is 16.06 million, so 15.33% of the outstanding shares have been sold short.
| Short Interest | 16.06M |
| Short Previous Month | 15.36M |
| Short % of Shares Out | 15.33% |
| Short % of Float | 16.68% |
| Short Ratio (days to cover) | 15.34 |
Income Statement
In the last 12 months, CRNX had revenue of $7.70 million and -$465.32 million in losses. Loss per share was -$4.95.
| Revenue | 7.70M |
| Gross Profit | -325.44M |
| Operating Income | -516.77M |
| Pretax Income | -465.14M |
| Net Income | -465.32M |
| EBITDA | -512.88M |
| EBIT | -516.77M |
| Loss Per Share | -$4.95 |
Full Income StatementBalance Sheet
The company has $1.03 billion in cash and $48.54 million in debt, with a net cash position of $979.35 million or $9.35 per share.
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 48.54M |
| Net Cash | 979.35M |
| Net Cash Per Share | $9.35 |
| Equity (Book Value) | 992.08M |
| Book Value Per Share | 10.38 |
| Working Capital | 963.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$377.92 million and capital expenditures -$5.76 million, giving a free cash flow of -$383.68 million.
| Operating Cash Flow | -377.92M |
| Capital Expenditures | -5.76M |
| Depreciation & Amortization | 3.89M |
| Net Borrowing | n/a |
| Free Cash Flow | -383.68M |
| FCF Per Share | -$3.66 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -6,714.77% |
| Pretax Margin | -6,043.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.43% |
| Shareholder Yield | -16.43% |
| Earnings Yield | -11.27% |
| FCF Yield | -9.29% |
Analyst Forecast
The average price target for CRNX is $76.63, which is 94.30% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $76.63 |
| Price Target Difference | 94.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 191.72% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRNX has an Altman Z-Score of 12.94 and a Piotroski F-Score of 3.
| Altman Z-Score | 12.94 |
| Piotroski F-Score | 3 |
